天眼查显示，金石成长股权投资（杭州）合伙企业（有限合伙）（简称"金石成长"）持有宇树科技4.7683%股权。盈信公司对金石成长认缴出资3 亿元，实缴出资1.8亿元。经首开股份了解，截至8月25日，基金的认缴规模为46.1亿元。据此计算，盈信公司持有基金的认缴份额比例约为 6.51%。 （原标题：7天大涨90%！600376，披露持有宇树科技比例！） 宇树科技宣布冲刺IPO后，首开股份(600376)近7个交易日股价累计大涨近90%。9月11日晚间，首开股份首次披露称，控股子公司间接持有的宇树 科技股权比例约为0.3%，同时个别机构股东在异动期出现减持。 首开股份本轮股价异动启动于9月3日，9月3日至11日期间的7个交易日，公司股票连续6个交易日涨停，11日盘中长时间封涨停板，至尾盘回落至 7%。7个交易日间，首开股份股价累计上涨约90%，总市值由68亿元飙升至129亿元，增长超61亿元。 从时间线上来看，首开股份股价异动与杭州宇树科技股份有限公司（简称"宇树科技"）上市的消息同步。9月2日，宇树科技宣布，预计将在2025 年10月至12月期间向证券交易所提交上市申请文件，届时公司的相关运营数据将正式披露。此前 ...

格隆汇9月12日丨和黄医药(00013.HK)宣布将于2025年10月31日(星期五)在中国上海举办会议分享最新 研发进展，并将通过网络同步直播。活动期间，和黄医药执行副总裁、研发负责人兼首席医学官石明博 士将分享公司的研发策略和愿景，包括概述公司抗体靶向偶联药物(ATTC)平台并重点介绍其首个候选 药物HMPL-A251，以及后期研发管线的最新进展。 ...

智通财经APP讯，中国宏桥(01378)发布公告，于2025年9月11日斥资246.36万港元回购股份10.05万股， 每股回购价格为24.2-24.8港元。 ...

中国宏桥(01378)发布公告，于2025年9月11日斥资246.36万港元回购股份10.05万股，每股回购价格为 24.2-24.8港元。 ...

OpenAI与微软在联合声明中表示："微软和OpenAI已签署一份关于双方合作下一阶段的非约束性谅解备 忘录(MOU)。""我们正积极推进，争取尽快敲定最终协议的合同条款。" OpenAI的转型计划将使现有非营利公司掌控公益公司(PBC)并直接分享其成功成果。OpenAI将持续保持 非营利组织性质。OpenAI称，非营利母公司的持续管控权将与公益公司股权挂钩，该股权价值将突破 1000亿美元，使其成为全球资源最雄厚的慈善机构之一。此次资本重组将助力OpenAI筹集实现使命所 需资金，并确保随着OpenAI PBC的成长，非营利组织的资源也将同步增长。 根据现有协议，微软是OpenAI的主要云服务提供商，并享有对其技术的优先使用权。但随着ChatGPT业 务的迅速扩张，OpenAI开始在谈判中寻求降低微软对其控制力度。据报道，双方谈判在过去数月一度 陷入僵局。微软曾希望掌控Windsurf(OpenAI今年初计划收购的一家AI编码公司)的相关技术，而OpenAI 坚持保持该公司的知识产权独立。最终收购未果，Windsurf创始人加入谷歌，其余团队被Cognition收 购。此外，在埃隆 马斯克对OpenAI的诉 ...

格隆汇9月12日丨中国宏桥(01378.HK)发布公告，2025年9月11日耗资246.36万港元回购10.05万股，回购 价格每股24.2-24.8港元。 ...

Core Viewpoint - Yangjie Technology announced a significant acquisition of 100% equity in Dongguan Better Electronics Technology Co., Ltd. for a total price of RMB 2.218 billion, following Better Electronics' failed IPO attempt [1][3]. Group 1: Acquisition Details - The acquisition will make Better Electronics a wholly-owned subsidiary of Yangjie Technology, and it is classified as a related party transaction, requiring approval from the shareholders' meeting [2]. - The transaction includes performance commitments, with a total net profit of no less than RMB 555 million from 2025 to 2027, excluding non-recurring gains and losses [2]. - The performance commitment parties will establish a holding platform, Dongguan Beiju, which will acquire at least RMB 716 million worth of Yangjie Technology shares through bulk trading, with these shares pledged to Yangjie Technology's subsidiary [2]. Group 2: Financial Performance and Valuation - Better Electronics' assessed value is RMB 2.22 billion, showing a significant increase compared to its book value of RMB 599 million, resulting in a valuation increase of RMB 1.621 billion, or 270.46% [3]. - The company's revenue for 2024 and Q1 2025 was RMB 837 million and RMB 218 million, respectively, with net profits of RMB 148 million and RMB 41.13 million [4]. Group 3: Strategic Implications - Better Electronics specializes in power electronic protection components and has received various industry accolades, indicating its strong market position [4]. - The acquisition is expected to enhance Yangjie Technology's product and technology portfolio, strengthen its market position in the power electronics sector, and create synergies in product offerings and customer bases [5]. - The collaboration is anticipated to improve research and development capabilities and technical integration, thereby enhancing the overall competitiveness of Yangjie Technology's core business [5].

Core Viewpoint - The announcement from the company reflects a strong commitment to its long-term value and future prospects, as demonstrated by the voluntary shareholding commitment from key executives [1] Group 1: Shareholder Commitment - Dr. Wu Jinzi and He Jingdao have voluntarily committed not to sell or pledge any shares they control until the release of three key clinical trial data points [1] - The three clinical data readouts include: (i) top-line data from the U.S. Phase I clinical study of ASC47 combined with semaglutide, expected by the end of September 2025; (ii) top-line data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in overweight or obese subjects, expected by December 2025; and (iii) top-line data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected by December 2025 [1] - As of the announcement date, the total number of voluntarily locked-up shares held by Dr. Wu and his wife amounts to 576 million shares, representing approximately 58.03% of the company's existing issued share capital (excluding treasury shares) [1]

于本公告日期，吴博士和吴夫人所持自愿禁售股份总数为 5.76亿股，约占公司现有已发行股本(不包括 库存股份)的58.03%。 智通财经APP讯，歌礼制药-B(01672)发布公告，为表达对公司长远价值及未来前景的坚定信心，吴劲梓 博士(歌礼创始人、董事会主席兼首席执行官、及公司控股股东，吴博士)，与何净岛(公司执行董事及控 股股东、吴博士的配偶，吴夫人)一起，已自愿承诺在如下3个临床数据读出前，不会出售(包括但不限 于出售或质押)任何由彼等或彼等各自控制的实体直接或间接实益拥有的公司股份：(i) ASC47联合司美 格鲁肽在肥胖受试者中进行的美国I期临床研究顶线数据，预计于2025年9月底获得;(ii) ASC30口服片在 肥胖或超重受试者中进行的美国13周IIa期临床研究顶线数据，预计于2025年12月获得;及(iii) ASC50在 健康受试者中进行的美国I期单剂量递增研究顶线数据，预计于2025年12月获得。 ...

Core Viewpoint - Alibaba's stock price surged by 8% on September 11, reaching its highest level since November 2021, driven by advancements in technology innovation and international business expansion [1][2] Group 1: Technology Innovation - Alibaba has begun using self-designed chips to train its AI models, marking a significant shift in China's tech landscape and a response to U.S. export restrictions on advanced chips [1] - The application of self-developed chips has already shown results in small AI models, enhancing Alibaba's competitiveness in the global market [1] Group 2: Financial Strategies - Alibaba priced approximately $3.2 billion in zero-coupon convertible senior bonds, with a maximum price set at $235.46 per American Depositary Share, reflecting a 60% premium [1] - The funds raised will primarily enhance cloud infrastructure capabilities and support international business expansion, with about 80% allocated to cloud infrastructure [1] Group 3: International Business Expansion - Alibaba is collaborating with Funan Liumu Cultural Industry to promote cross-border e-commerce, aiding the digital transformation and globalization of traditional industries [2] - This partnership is expected to boost the export of cultural products and enhance Alibaba's platform influence, creating new economic growth opportunities for the local area [2] Group 4: Investor Sentiment - Recent data indicates a positive shift in investor sentiment towards Alibaba, with net buying from southbound funds for 15 consecutive days, reflecting optimism about the company's growth prospects [2] - The strategic initiatives in technology and international market expansion are key drivers behind the stock price increase [2]